Editor’s Note: Related tickers: VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Amgen, Inc. (NASDAQ:AMGN)
Pfizer Elected to Continue Development of Tamper-resistant Painkiller Remoxy – VIVUS, ARNA, ARIA, MNKD, MRK, PFE (FiscalInsider)
Investors in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) saw new options become available this week, for the April 2014 expiration. …VIVUS, Inc. (NASDAQ:VVUS) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. For Portfolio Grader’s specific subcategory of Equity, VVUS also gets an F. The stock price has dropped 6.1% over the past month, worse than the 1.3% decrease the NASDAQ has seen over the same period of time VIVUS, Inc. (NASDAQ:VVUS) shares plunged -0.81% to $12.23 in last trading session. Stock traded in range of $12.00 – $12.41.
Onyx trials cloud Amgen deal (TheDeal)
A Bloomberg article that ran Aug. 14 cited anonymous sources saying that Amgen, Inc. (NASDAQ:AMGN)‘s $10 billion, $120 per share acquisition of Onyx Pharmaceuticals Inc. was hanging on whether Amgen could see results of a clinical trial for Onyx’s Kyprolis. However, the reference to the study results was ambiguous and left parties tracking the deal trying to figure out which trial the sources were alluding to and whether access to the data could truly be a deal-breaker.
Biotech Stocks in News, VIVUS Inc, Arena Pharmaceuticals Inc, Ariad Pharmaceuticals Inc, MannKind Corporation, Affymax, Pfizer Inc (FiscalInsider)
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a controversial stock among biotech investors. The bulls believe that increasing rates of global obesity will inevitably trigger more sales of its new weight loss drug, Belviq, which was approved by the FDA last June. However, the bears believe that lingering safety concerns regarding Belviq and the company’s insistence on combining the treatment with other medications could cause problems down the road. Arena shares plunged -0.44% to $6.80 in last trading session. Stock traded in range of $6.75 – $6.91.
Amgen Rating Reiterated by Goldman Sachs Group Inc. (AMGN) (WatchlistNews)
Goldman Sachs Group Inc. reiterated their buy rating on shares of Amgen, Inc. (NASDAQ:AMGN) in a research report released on Friday morning, ARN reports. A number of other firms have also recently commented on AMGN. Analysts at RBC Capital raised their price target on shares of Amgen, Inc. (NASDAQ:AMGN) from $120.00 to $125.00 in a research note to investors on Thursday, August 1st. They now have an outperform rating on the stock.
Investor’s Alert -Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Plug Power Inc (NASDAQ:PLUG), Targacept, Inc. (NASDAQ:TRGT), Inc. (NASDAQ:GTXI) (Techsonian)
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. …Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) managed to keep its gain at 1.44% on below normal -average volume of 2.71M shares. The stock settled at $7.06 after floating in a range of $6.95 to $7.13. Significantly, its latest price is at a discount of -14.25% to its 200-day moving average price.
